Evotec (1EVT) Price & Analysis
1EVT Stock Chart & Stats
- Day’s Range
- EUR 2.88 - EUR 2.88
- 52-Week Range
- EUR 2.00 - EUR 8.00
- Previous Close
- EUR 2.93
- Volume
- 0
- Average Volume (3M)
- 1,291
- Market Cap
- EUR 500.65M
- Enterprise Value
- EUR 898.74M
- Total Cash (Recent Filing)
- EUR 465.59M
- Total Debt (Recent Filing)
- EUR 475.87M
- Price to Earnings (P/E)
- ―
- Beta
- 0.78
- Next Earnings
- Nov 05, 2026
- EPS Estimate
- -0.32
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Integrated R&D Platform
Evotec’s integrated platform covers multiple stages of drug research, allowing it to support customers from discovery through development. This breadth can deepen client relationships, broaden revenue opportunities, and provide a durable foundation across changing pharmaceutical R&D priorities.
Manageable Headline Leverage
Debt-to-equity of about 0.71 is not extreme relative to the company’s equity base, providing a more manageable leverage profile than the loss figures alone might suggest. This offers some financial flexibility while Evotec works to improve profitability and cash generation.
Losses Narrowed Before TTM Deterioration
The material reduction in losses from 2024 to 2025 indicates that Evotec has demonstrated some capacity to improve earnings performance. Although the TTM result later weakened, this prior progress provides evidence that profitability can respond to operational or portfolio improvements.
Bears Say
Persistent Unprofitability And Margin Pressure
Evotec’s sustained losses and sharply compressed margins weaken the economics of its operating model and reduce its ability to fund growth internally. The gap between current and historical gross margins suggests profitability recovery may require meaningful improvement in mix, pricing, or costs.
Negative Cash Generation
Negative operating and free cash flow means Evotec is currently consuming cash rather than self-funding its activities. The reversal from positive operating cash flow in earlier years also points to unstable cash conversion, increasing reliance on balance-sheet resources or external funding.
Eroding Equity Base
The substantial decline in equity reflects the cumulative effect of sustained losses and reduces the financial cushion available to absorb further weakness. Persistently negative returns on shareholder capital could continue eroding that base, limiting flexibility for investment and strategic execution.
1EVT FAQ
What was Evotec’s price range in the past 12 months?
What is Evotec’s market cap?
When is Evotec’s upcoming earnings report date?
How were Evotec’s earnings last quarter?
Is Evotec overvalued?
Does Evotec pay dividends?
What is Evotec’s EPS estimate?
How many shares outstanding does Evotec have?
What happened to Evotec’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Evotec?
What is the TipRanks Smart Score and how is it calculated?
Evotec Stock Smart Score
Company Description
Evotec
Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a diverse array of health challenges, including diabetes and its related complications, various fibrotic conditions, infectious diseases, disorders of the central nervous system, oncological conditions, pain management, inflammatory and immunological ailments, rare diseases, respiratory illnesses, and women's health concerns. Evotec SE has forged partnerships with a number of significant players in the sector, such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. The company, initially incorporated as Evotec AG in 1993, underwent a name change to Evotec SE in April 2019 and maintains its corporate headquarters in Hamburg, Germany.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Christian Wojczewski
- Employees
- 4,461
- Website
- www.evotec.com
- Address
- Essener Bogen 7, Hamburg, HA, 22419, DE
Evotec (1EVT) Earnings & Revenues
1EVT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 6 | 10 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 3 | 0 | 9 |